Global Eftrenonacog Alfa Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Eftrenonacog Alfa Market Research Report 2024
Eftrenonacog alfa is a long-acting recombinant fusion protein used in the treatment of hemophilia B. It is comprised of a single molecule of human factor IX (FIX) covalently linked to the constant region (Fc) domain of human IgG1 via recombinant DNA technology in a human embryonic kidney cell line (HEK293H) 1. The presence of the Fc domain extends the terminal half-life which confers clinical benefits of prolonged therapeutic efficacy, less frequent intravenous injections for patient convenience and improved adherence to prophylaxis.
According to Mr Accuracy reports’s new survey, global Eftrenonacog Alfa market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Eftrenonacog Alfa market research.
Key manufacturers engaged in the Eftrenonacog Alfa industry include Vetter Pharma-Fertigung GmbH & Co.KG, Sanofi Aventis, Bioverativ Therapeutics Inc., Biogen Inc and SWEDISH ORPHAN BIOVITRUM AB, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Eftrenonacog Alfa were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Eftrenonacog Alfa market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Eftrenonacog Alfa market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Vetter Pharma-Fertigung GmbH & Co.KG
Sanofi Aventis
Bioverativ Therapeutics Inc.
Biogen Inc
SWEDISH ORPHAN BIOVITRUM AB
Segment by Type
250IU
500IU
1000IU
2000IU
Hemophilia
Surgical Bleeding
Long-term Bleeding Prevention
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Eftrenonacog Alfa report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Eftrenonacog Alfa market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Eftrenonacog Alfa market research.
Key manufacturers engaged in the Eftrenonacog Alfa industry include Vetter Pharma-Fertigung GmbH & Co.KG, Sanofi Aventis, Bioverativ Therapeutics Inc., Biogen Inc and SWEDISH ORPHAN BIOVITRUM AB, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Eftrenonacog Alfa were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Eftrenonacog Alfa market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Eftrenonacog Alfa market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Vetter Pharma-Fertigung GmbH & Co.KG
Sanofi Aventis
Bioverativ Therapeutics Inc.
Biogen Inc
SWEDISH ORPHAN BIOVITRUM AB
Segment by Type
250IU
500IU
1000IU
2000IU
Segment by Application
Hemophilia
Surgical Bleeding
Long-term Bleeding Prevention
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Eftrenonacog Alfa report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices